iBio (NASDAQ:IBIO) Upgraded at JonesTrading

JonesTrading upgraded shares of iBio (NASDAQ:IBIO) to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research firms have also issued reports on IBIO. Wall Street Zen upgraded shares of iBio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a research note on Monday, December 29th. Finally, Lifesci Capital upgraded iBio to a “strong-buy” rating in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, iBio has an average rating of “Buy”.

iBio Trading Up 5.2%

Shares of NASDAQ:IBIO opened at $2.83 on Monday. The company has a 50 day moving average price of $2.30. iBio has a 52 week low of $0.56 and a 52 week high of $6.89. The stock has a market cap of $97.76 million, a P/E ratio of -2.83 and a beta of 1.18.

iBio (NASDAQ:IBIO) last released its earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01).

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.